Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin + paclitaxel + trastuzumab as primary systemic therapy for operable or locally advanced breast cancer
2008-001369-27Phase 2Active
- Sponsor
- San Salvatore Hospital of L'Aquila
- Start
- Mar 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, paclitaxel and trastuzumab in breast cancer and inflammatory breast cancer (IBC), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoint: Pathological complete response rate. Started Mar 2009; status: active.
02
Drugs
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2008-001369-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001369-27.